跳至主要内容
临床试验/NCT01514162
NCT01514162已完成不适用

Post-Approval Study Protocol of the St. Jude Medical Trifecta Valve

Abbott Medical Devices12 个研究点 分布在 1 个国家目标入组 245 人开始时间: 2012年2月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
245
试验地点
12
主要终点
Late Adverse Event Incidence

研究概览

简要总结

To further evaluate the long term clinical safety and effectiveness of the Trifecta valve

详细描述

To further evaluate the long term clinical safety and effectiveness of the Trifecta valve in subjects who had a Trifecta valve implanted during the IDE study.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects implanted with a Trifecta valve at one of the US sites of the IDE study.
  • Subject met eligibility criteria of IDE study
  • Subject agrees to complete study follow-up visits
  • Subject provides written informed consent

排除标准

  • Subject currently participating in another device or drug study
  • Subject unable or unwilling to return for study follow-up visits

研究组 & 干预措施

Trifecta Valve Group

Experimental

Subjects implanted with a Trifecta valve.

干预措施: Trifecta valve (Device)

结局指标

主要结局

Late Adverse Event Incidence

时间窗: 5 years

Late patient years are calculated from 31 days post-implant to the date of the last follow-up visits (or contact) or adverse events. Late Patient year calculation:\[(Number of late adverse events/sum of late patient years) x 100\]

次要结局

  • Characterize Patient NYHA Functional Classification Status(5 years)
  • Report the Hemodynamic Performance of the Valve(5 years)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (12)

Loading locations...

相似试验